Gemmer Asset Management’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-45
| Closed | -$3K | – | 666 |
|
|
2022
Q1 | $3K | Buy |
45
+8
| +22% | +$580 | ﹤0.01% | 1086 |
|
|
2021
Q4 | $4K | Hold |
37
| – | – | ﹤0.01% | 1062 |
|
|
2021
Q3 | $3K | Hold |
37
| – | – | ﹤0.01% | 1129 |
|
|
2021
Q2 | $3K | Hold |
37
| – | – | ﹤0.01% | 1302 |
|
|
2021
Q1 | $4K | Hold |
37
| – | – | ﹤0.01% | 1157 |
|
|
2020
Q4 | $2K | Hold |
37
| – | – | ﹤0.01% | 1329 |
|
|
2020
Q3 | $2K | Hold |
37
| – | – | ﹤0.01% | 1195 |
|
|
2020
Q2 | $3K | Hold |
37
| – | – | ﹤0.01% | 1049 |
|
|
2020
Q1 | $2K | Sell |
37
-3
| -8% | -$170 | ﹤0.01% | 1079 |
|
|
2019
Q4 | $3K | Hold |
40
| – | – | ﹤0.01% | 1145 |
|
|
2019
Q3 | $2K | Hold |
40
| – | – | ﹤0.01% | 1251 |
|
|
2019
Q2 | $3K | Sell |
40
-45
| -53% | -$3.31K | ﹤0.01% | 1129 |
|
|
2019
Q1 | $7K | Hold |
85
| – | – | ﹤0.01% | 850 |
|
|
2018
Q4 | $7K | Hold |
85
| – | – | ﹤0.01% | 773 |
|
|
2018
Q3 | $15K | Hold |
85
| – | – | ﹤0.01% | 508 |
|
|
2018
Q2 | $11K | Hold |
85
| – | – | ﹤0.01% | 658 |
|
|
2018
Q1 | $9K | Hold |
85
| – | – | ﹤0.01% | 734 |
|
|
2017
Q4 | $7K | Hold |
85
| – | – | ﹤0.01% | 841 |
|
|
2017
Q3 | $7K | Hold |
85
| – | – | ﹤0.01% | 815 |
|
|
2017
Q2 | $6K | Buy |
85
+2
| +2% | +$140 | ﹤0.01% | 862 |
|
|
2017
Q1 | $6K | Buy |
83
+1
| +1% | +$66 | ﹤0.01% | 868 |
|
|
2016
Q4 | $5K | Hold |
82
| – | – | ﹤0.01% | 902 |
|
|
2016
Q3 | $5K | Hold |
82
| – | – | ﹤0.01% | 897 |
|
|
2016
Q2 | $6K | Hold |
82
| – | – | ﹤0.01% | 789 |
|
|
2016
Q1 | $5K | Buy |
82
+45
| +122% | +$2.73K | ﹤0.01% | 823 |
|
|
2015
Q4 | $2K | Hold |
37
| – | – | ﹤0.01% | 1120 |
|
|
2015
Q3 | $2K | Buy |
37
+16
| +76% | +$971 | ﹤0.01% | 1096 |
|
|
2015
Q2 | $1K | Buy |
21
+5
| +31% | +$273 | ﹤0.01% | 1253 |
|
|
2015
Q1 | $1K | Sell |
16
-8
| -33% | -$307 | ﹤0.01% | 1291 |
|
|
2014
Q4 | $1K | Sell |
24
-16
| -40% | -$520 | ﹤0.01% | 1286 |
|
|
2014
Q3 | $1K | Sell |
40
-6
| -13% | -$199 | ﹤0.01% | 1282 |
|
|
2014
Q2 | $2K | Buy |
46
+12
| +35% | +$487 | ﹤0.01% | 1177 |
|
|
2014
Q1 | $1K | Buy |
+34
| New | +$1.42K | ﹤0.01% | 1292 |
|
Other funds holding LGND
SDJVC
SIMG
CC
Gemmer Asset Management's LGND Position: Q2 2022 in Review
Gemmer Asset Management sold out of Ligand Pharmaceuticals (LGND) in Q2 2022, closing a stake of 45 shares — an estimated $3K sold.
Gemmer Asset Management first reported a position in LGND in Q1 2014 and held it in 33 quarters. The position peaked at $15K in Q3 2018. 197 funds tracked by Wall St. Rank hold LGND as of Q2 2022.
- Gemmer Asset Management reported no remaining Ligand Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
- Gemmer Asset Management sold 45 Ligand Pharmaceuticals shares in Q2 2022, an estimated $3K.
- Gemmer Asset Management first reported a position in Ligand Pharmaceuticals in Q1 2014 and held it in 33 quarters.
- Gemmer Asset Management's Ligand Pharmaceuticals position peaked at $15K in Q3 2018.
- 197 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2022.
Based on Gemmer Asset Management's 13F filing for Q2 2022, filed 22 Jul 2022.